National Institute of Criminology

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations

Cyclin-dependent Kinase 4/6, Breast Oncology, Inhibitor Palbociclib +11

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Fabrice André, Ruth O’Regan, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2014 · 489 citations

Advanced Breast Cancer, Breast Oncology, Oncology +8

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 469 citations · Full text

Radiation Medicine, Radiation Therapy, Medicine +10

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

Marcia S. Brose, Bruce Robinson, Steven I. Sherman et al. · The Lancet Oncology · 2021 · 221 citations

Nuclear Medicine, Medicine, Radionuclide Therapy +12

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

Denis Soulières, Sandrine Faivre, Éva Remenár et al. · The Lancet Oncology · 2017 · 214 citations

Placebo-controlled Phase 2, Neoadjuvant Therapy, Medicine +7